Why the study?
Does the efficacy of substrate-guided VT ablation differ between patients with ischaemic versus non-ischaemic dilated cardiomyopathy?
Population
142 patients with structural heart disease, specifically ischaemic cardiomyopathy and non-ischaemic dilated…
Design
Cohort
Follow-up
mean 641 ± 301 days
Authors
Loading...
May warrant etiology-specific ablation strategies in NIDCM; leaves open need for randomized validation before practice change.
Does the efficacy of substrate-guided VT ablation differ between patients with ischaemic versus non-ischaemic dilated cardiomyopathy?
Substrate-guided VT ablation is less effective in patients with non-ischaemic dilated cardiomyopathy compared to those with ischaemic cardiomyopathy, with long-term outcomes strongly dependent on acute procedural success.
Proietti et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: